Course of CAEL-101 patients with cardiac and/or renal involvement at enrollment. Cardiac and renal responses were calculated from trial enrollment. Patients 6, 7, 9, and 15 had both cardiac and renal involvement. Patients 4 and 13-17 experienced cardiac response by NT-proBNP measurement; patients 3, 10, 12, 15, and 18 experienced renal response by proteinuria measurement. Patients 2, 7, 13, 15, and 16 developed cardiac progression; patients 3, 8, 10, and 11 developed renal progression by eGFR measurement. Patients 11-13, 15, 16, and 18 developed hematologic progression. Patients 2, 3, 7, 12, and 13 died from progressive AL amyloidosis (patient 12 from novel heart failure not present at time of CAEL-101 initiation); patient 6 died from venous thromboembolic complications; patient 14 died from gastric cancer; and patient 16 died from progressive multiple myeloma.
Figure 2.

Course of CAEL-101 patients with cardiac and/or renal involvement at enrollment. Cardiac and renal responses were calculated from trial enrollment. Patients 6, 7, 9, and 15 had both cardiac and renal involvement. Patients 4 and 13-17 experienced cardiac response by NT-proBNP measurement; patients 3, 10, 12, 15, and 18 experienced renal response by proteinuria measurement. Patients 2, 7, 13, 15, and 16 developed cardiac progression; patients 3, 8, 10, and 11 developed renal progression by eGFR measurement. Patients 11-13, 15, 16, and 18 developed hematologic progression. Patients 2, 3, 7, 12, and 13 died from progressive AL amyloidosis (patient 12 from novel heart failure not present at time of CAEL-101 initiation); patient 6 died from venous thromboembolic complications; patient 14 died from gastric cancer; and patient 16 died from progressive multiple myeloma.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal